These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 26206012)

  • 21. Preparation of budesonide-dextran conjugates using glutarate spacer as a colon-targeted drug delivery system: in vitro/in vivo evaluation in induced ulcerative colitis.
    Varshosaz J; Emami J; Ahmadi F; Tavakoli N; Minaiyan M; Fassihi A; Mahzouni P; Dorkoosh F
    J Drug Target; 2011 Feb; 19(2):140-53. PubMed ID: 20429772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Colitis ulcerosa - a diagnostic and therapeutic update].
    Fischer S; Neurath MF; Atreya R
    MMW Fortschr Med; 2016 Apr; 158(8):77-80. PubMed ID: 27116171
    [No Abstract]   [Full Text] [Related]  

  • 23. [Extra-intestinal manifestations and complications in chronic active ulcerative colitis in childhood and adolescence].
    Hüppe D; Schenck B; Tromm A
    Dtsch Med Wochenschr; 1999 Jul; 124(27):824-8. PubMed ID: 10432942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Topical steroids in chronic inflammatory bowel diseases].
    Fleig WE
    Internist (Berl); 1997 Dec; 38(12):1154-9. PubMed ID: 9465320
    [No Abstract]   [Full Text] [Related]  

  • 25. Controlled, open, randomized multicenter trial comparing the effects of treatment on quality of life, safety and efficacy of budesonide foam and betamethasone enemas in patients with active distal ulcerative colitis.
    Hammond A; Andus T; Gierend M; Ecker KW; Scholmerich J; Herfarth H;
    Hepatogastroenterology; 2004; 51(59):1345-9. PubMed ID: 15362749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Ulcerative colitis. Acute episode].
    Reissmann A; Bischoff SC; Fleig W
    Z Gastroenterol; 2004 Sep; 42(9):994-8. PubMed ID: 15455271
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment of distal ulcerative colitis: now the patients have the choice.
    Schölmerich J
    Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):685-7. PubMed ID: 10730560
    [No Abstract]   [Full Text] [Related]  

  • 28. [Mesalazine granules instead of tablets. New ulcerative colitis therapy confirmed also in general practice routine].
    MMW Fortschr Med; 2004 Jun; 146(24):53. PubMed ID: 15366501
    [No Abstract]   [Full Text] [Related]  

  • 29. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent.
    Cohen HD; Das KM
    J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S150-4. PubMed ID: 16885699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Ulcerative colitis. When is standard therapy enough?].
    Stange EF
    MMW Fortschr Med; 2000 Oct; 142(41):39-40. PubMed ID: 11085075
    [No Abstract]   [Full Text] [Related]  

  • 31. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
    Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Drug therapy for ulcerative colitis: salazosulfapyridine and 5-ASA].
    Jo Y; Matsumoto T; Iida M
    Nihon Rinsho; 2005 May; 63(5):820-4. PubMed ID: 15881176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MMX mesalamine.
    Baker DE
    Rev Gastroenterol Disord; 2006; 6(3):146-52. PubMed ID: 16957657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
    Kamm MA; Sandborn WJ; Gassull M; Schreiber S; Jackowski L; Butler T; Lyne A; Stephenson D; Palmen M; Joseph RE
    Gastroenterology; 2007 Jan; 132(1):66-75; quiz 432-3. PubMed ID: 17241860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
    Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
    Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials.
    Zhu Y; Tang RK; Zhao P; Zhu SS; Li YG; Li JB
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):487-94. PubMed ID: 22465970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review article: induction therapy for patients with active ulcerative colitis.
    Travis SP
    Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 1():10-6. PubMed ID: 16939424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.
    Richter JM; Kushkuley S; Barrett JA; Oster G
    Aliment Pharmacol Ther; 2012 Aug; 36(3):248-56. PubMed ID: 22690748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
    Segars LW; Gales BJ
    Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute pancreatitis secondary to long-term 5- aminosalicylic acid therapy in a patient with ulcerative colitis: a case-report.
    Ouakaa-Kchaou A; Gargouri D; Kochlef A; Bibani N; Elloumi H; Trad D; Kharrat J
    Tunis Med; 2014 Jun; 92(6):423. PubMed ID: 25741849
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.